Therapy Areas: Allergy
US FDA grants Breakthrough Therapy designation to Ridgeback Biotherapeutics' Ebola treatment
9 September 2019 - The US Food and Drug Administration (FDA) has granted Ridgeback Biotherapeutics LP, a biotechnology company, Breakthrough Therapy designation for its mAb114, an experimental Ebola t...
VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections
30 August 2019 - - US-based pharmaceutical company VenatoRx Pharmaceuticals has initiated enrollment in its Phase 3 trial of cefepime/VNRX-5133 in patients with complicated urinary tract infections (c...
VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio
22 August 2019 - - US-based VenatoRx Pharmaceuticals has added pharmaceutical industry veterans, Jennifer Ellis, Dr. Paul McGovern and Lauren P. Tornetta to its development team, the company said.
Signant Health names new clinical vice president, Internal Medicine
21 August 2019 - United States-based Signant Health has added Anthony Todd Everhart, MD, FACP to the Signant Health Science and Medicine Team as clinical vice president, Internal Medicine, it was repo...
RTI International wins FDA approval for pretomanid for treating drug-resistant TB
15 August 2019 - Research company RTI International reported on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) for the new drug pretomanid for treating Extensively Dr...
First Patient Enrolled in CARES10, a Phase 3, Multi-Center Study to Assess a 10 % Intravenous Immunoglobulin in Adults with Primary Immunodeficiency Disease
12 August 2019 - - US-based plasma-derived therapeutic products maker Kedrion Biopharma has initiated the CARES10 (Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10...
Related Headlines

Dr. Reddy's Launches OTC, Store-Brand Equivalent of Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets in the US Market

LifeMax Receives Rare Pediatric Disease Designation for LM-030 for the Treatment of Netherton Syndrome

First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum Disorder

Dr. Reddy's Launches Over-the-Counter Store Brand Equivalent of Mucinex D Extended Release Tablets in Two Strengths in the US Market

CEL-SCI Collaborators Presents Data for New Vaccine in the Treatment of Rheumatoid Arthritis at the International Conference on Immunity and Immunochemistry Meeting

First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

Vedanta enrols first patient in Phase 1b/2 clinical study of VE416

Modag Launches Out of Stealth Mode with series A Financing of EUR 12 m to Develop Treatments for Parkinsonian Disorders, Including Multiple System Atrophy

LifeMax Receives Orphan Drug Designation from the United States Food and Drug Administration For LM-030 For The Treatment of Netherton Syndrome

Immunomic Therapeutics Promotes Heiland to Chief Scientific Officer

Axial Biotherapeutics Receives USD 10m Investment from Taiho Ventures to Access Axial's Expertise in the Gut-Brain Axis

Sirion Biotech Licenses Technology to National Institute of Allergy and Infectious Diseases to Boost Clinical Efficacy of Lentivector Gene Therapy for X-Linked SCID

Aimmune Therapeutics Discusses AR101's Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting

ALK-Abelló announces European approval for its tree SLIT-tablet for allergic rhinitis

Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy